Connect to other sites within the UBM Medica Network
Agent Orange Exposure Linked to Myeloma Precursor Risk
Vietnam War veterans exposed to Agent Orange as part of Operation Ranch Hand were at double the risk for monoclonal gammopathy of undetermined significance, a precursor to multiple myeloma, according to results of a new study.
FDA Approves New Drug For Chemo-Related Nausea and Vomiting
The US Food and Drug Administration has approved rolapitant for the prevention of delayed phase nausea and vomiting associated with chemotherapy.
Sentinel Node Positivity Less Likely in Presence of Melanoma Regression
Metastasis to sentinel lymph nodes was significantly lower among patients with melanoma with histologic regression of their disease compared with those without regression.
Perineural Invasion Linked With Prostate Cancer Bone Metastasis
Perineural invasion was a significant predictor of increased risk for bone metastases in men with prostate cancer who had suspicion for bone metastases after a whole-body bone scan.
Combined Lenalidomide/Rituximab Active in Recurrent Follicular Lymphoma
Combined treatment with lenalidomide/rituximab resulted in better clinical response in patients with recurrent follicular lymphoma than did lenalidomide alone.
Total Resection Associated With Better Survival in Atypical, Malignant Meningioma
Gross total resection was associated with significantly lower all-cause mortality in patients with atypical and malignant meningioma, according to a new study.
Bevacizumab Fails to Improve Angiosarcoma Outcomes With Paclitaxel
Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.